Regenerative Medicine in Pharma Market Size, Share & Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical), & Segment Forecast 2022-2028

Description

List of Tables

Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical), and Segment Forecast, 2022-2027

The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027. The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.

This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.

The regenerative medicine in pharma market size was valued at US$29.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during the forecast period (2022-2027). The market is driven by the growing prevalence of chronic diseases, genetic disorders, and cancer and technological advancements in stem-cell therapies.

Scope

Overview of regenerative medicine in pharma market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
Regenerative medicine in pharma market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application, and geographic segments.
Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.
The competitive landscape: an examination of the positioning of leading players in regenerative medicine in pharma market.

Reasons to Buy

This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
Accompanying GlobalData's Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in regenerative medicine in pharma markets.
The report also highlights key product, therapeutic area segments.
With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in regenerative medicine in pharma market.

Product Code: GDPH-SC-MR005

CHAPTER 01 Executive Summary
1.1 Regenerative Medicine in Pharma Market Snapshot
1.2 Regenerative Medicine in Pharma Market- Key Findings
CHAPTER 02 Market Landscape
2.1 Market Definition
2.2 Market Scope and Segmentation
2.3 Industry Trends
- 2.3.1 HEALTHCARE TRENDS
- 2.3.2 REGULATORY TRENDS
2.4 Opportunities in Regenerative Medicine in Pharma
- 2.4.1 GENE THERAPY
- 2.4.2 CELL THERAPY
- 2.4.3 TISSUE ENGINEERED PRODUCTS AND BIOMATERIALS
2.5 Regenerative Medicines in Clinical Trials
CHAPTER 03 Regenerative Medicine in Pharma Value Chain
3.1 Value Chain Analysis
- 3.1.1 ARM CLASSIFICATION OF REGENERATIVE MEDICINE
CHAPTER 04 Regulatory and Market Access
4.1 Differences Between Conventional Therapies and Stem Cell Therapies in Clinical Trials
4.2 US
- 4.2.1 REGULATORY
- 4.2.2 MARKET ACCESS
4.3 Europe
4.4 Regulation of Regenerative Medicine in the US and Europe
4.5 Japan
4.6 South Korea
CHAPTER 05 Marketed Products
5.1 Overview
- 5.1.1 LEADING CELL-BASED IMMUNOTHERAPY TREATMENTS
- 5.1.2 LEADING GENE THERAPY TREATMENTS
- 5.1.3 LEADING CELL-THERAPIES TREATMENT
- 5.1.4 LEADING TISSUE ENGINEERED PRODUCTS TREATMENTS
CHAPTER 06 Regenerative Medicine Pipeline Products in the 8MM
6.1 Late-Stage Gene Therapy Products
6.2 Late-Stage Gene-Modified Cell Therapy Products
6.3 Late-Stage Cell Therapy Products
6.4 Late-Stage Tissue-Engineered Treatment
CHAPTER 07 Regenerative Medicine in Pharma Industry Analysis
7.1 Regenerative Medicine in Pharma Market Structure - PORTER's Analysis
7.2 Deals in Regenerative Medicine in Pharma
7.3 Funding in Regenerative Medicine in Pharma
CHAPTER 08 Global Regenerative Medicine in Pharma Revenue Opportunity
8.1 Global Digital Biomarkers Market
8.2 COVID-19 Pandemic
CHAPTER 09 Regenerative Medicine in Pharma Product Outlook
9.1 Regenerative Medicine in Pharma - Product Dive
- 9.1.1 TISSUE-ENGINEERED PRODUCTS
- 9.1.2 GENE THERAPIES
- 9.1.3 CELL THERAPIES
- 9.1.4 OTHERS
CHAPTER 010 Regenerative Medicine in Pharma Therapeutic Area Outlook
10.1 Regenerative Medicine in Pharma - Therapeutic Area Dive
- 10.1.1 ONCOLOGY
- 10.1.2 MUSCULOSKELETAL DISORDERS
- 10.1.3 IMMUNOLOGY AND INFLAMMATION
- 10.1.4 DERMATOLOGY
- 10.1.5 OTHERS
CHAPTER 011 Regenerative Medicine in Pharma Regional Outlook
11.1 Regenerative Medicine in Pharma - Regional Deep Dive
- 11.1.1 NORTH AMERICA
- 11.1.2 EUROPE
- 11.1.3 ASIA-PACIFIC
- 11.1.4 ROW
CHAPTER 012 Trends, Drivers, and Challenges
12.1 Regenerative Medicine in Pharma - Market Trends
- 12.1.1 CONSTANT INNOVATION IN CELL ENGINEERING TECHNIQUES:
- 12.1.2 INCREASING APPLICATION OF GENE THERAPY:
- 12.1.3 FAST TRACK APPROVALS AND MULTIPLE DRUGS IN LAST STAGES OF PIPELINE
- 12.1.4 THE MOMENTUM CREATED BY ALLOGENIC THERAPEUTICS CONTINUES TO DRIVE MARKET:
- 12.1.5 INCREASING APPLICATIONS OF 3D PRINTING IN REGENERATIVE MEDICINE:
12.2 Regenerative Medicine in Pharma - Market Drivers
- 12.2.1 GROWING PREVALENCE OF CHRONIC DISEASES, GENETIC DISORDERS, AND CANCER
- 12.2.2 TECHNOLOGICAL ADVANCEMENTS IN STEM-CELL THERAPIES
- 12.2.3 INCREASED INVESTMENT BY KEY PLAYERS IN R&D OF THE REGENERATIVE MEDICINES
12.3 Regenerative Medicine in Pharma - Market Challenges
- 12.3.1 GENE THERAPY
- 12.3.2 CELL THERAPY
- 12.3.3 TISSUE-ENGINEERED PRODUCTS AND BIOMATERIALS
CHAPTER 013 Regenerative Medicine in Pharma Market Vendor Snapshot
COMPANY SNAPSHOT: NOVARTIS AG
COMPANY SNAPSHOT: GILEAD
COMPANY SNAPSHOT: AMGEN
COMPANY SNAPSHOT: BRISTOL-MYERS SQUIBB COMPANY
COMPANY SNAPSHOT: BLUE BIRD BIO
COMPANY SNAPSHOT: JOHNSON & JOHNSON
COMPANY SNAPSHOT: BIOMARIN PHARMACEUTICAL INC
COMPANY SNAPSHOT: PTC THERAPEUTICS
COMPANY SNAPSHOT: ORCHARD THERAPEUTICS
COMPANY SNAPSHOT: VERICEL CORPORATION
CHAPTER 014 Appendix
14.1 Methodology
14.2 About US

Product Code: GDPH-SC-MR005

List of Tables

Table 1 Key Trends Overview
Table 2 Regenerative Medicine classification
Table 3 Research Scope and Segmentation
Table 4 Healthcare Trends
Table 5 Regulatory Trends
Table 6 Cell-Based Immunotherapy
Table 7 Gene Therapy
Table 8 Cell Therapies
Table 9 Tissue-Engineered Products
Table 10 Deals in Regenerative Medicine in Pharma
Table 11 Funding Activity in the Regenerative medicine in Pharma Industry
Table 12 Regenerative Medicine in Pharma Market
Table 13 Regenerative Medicine in Pharma by Product, 2020-2027 ($Mn)
Table 14 Regenerative Medicine in Pharma by Therapeutic Area, 2020-2027 ($Mn)
Table 15 Regenerative Medicine in Pharma by Region, 2020-2027 ($Mn)
Table 16 North America Regenerative Medicine in Pharma by Country, 2020-2027 ($Mn)
Table 17 Europe Regenerative Medicine in Pharma by Country, 2020-2027 ($Mn)
Table 18 Asia-Pacific Regenerative Medicine in Pharma by Country, 2020-2027 ($Mn)

List of Figures

Figure 1 Market Snapshot ($Mn)
Figure 2 Key Segment Performance Snapshot
Figure 3 History of Regenerative Medicine Development in 8MM
Figure 4 Clinical Trials
Figure 5 Clinical Trials by Therapy Areas
Figure 6 Regenerative Medicine in Pharma Value Chain
Figure 7 Regenerative Medicine in Pharma Value Chain
Figure 8 Regenerative Medicine in Pharma Value Chain
Figure 9 Regenerative Medicine in Pharma Value Chain
Figure 10 Regenerative Medicine Clinical Trial Model
Figure 11 Regenerative Medicine Clinical Trial Model
Figure 12 Regenerative Medicine in Pharma Value Chain
Figure 13 Marketed Regenerative Medicine by Type and Region
Figure 14 Marketed Regenerative Medicine by Therapy Area
Figure 15 Pipeline Products by Type, Phase, and Therapy Area
Figure 16 Gene Therapy Products
Figure 17 Gene-Modified Cell Therapy Products
Figure 18 Cell Therapy Products
Figure 19 Tissue-Engineered Treatment
Figure 20 Global Regenerative Medicine in Pharma PORTER's Five Force Analysis
Figure 21 Global Regenerative medicine in Pharma Market - Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 22 Regenerative Medicine in Pharma by Product - Market Overview ($Mn)
Figure 23 Regenerative Medicine in Pharma by Product - 2021 & 2027 (%)
Figure 24 Tissue-engineered Products Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 25 Gene Therapies Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 26 Cell Therapies Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 27 Others Product Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 28 Regenerative Medicine in Pharma by Therapeutic Area - Market Overview ($Mn)
Figure 29 Regenerative Medicine in Pharma by Therapeutic Area - 2021 & 2027 (%)
Figure 30 Oncology Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 31 Musculoskeletal Disorders Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 32 Immunology and Inflammation Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 33 Dermatology Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 34 Others Therapeutic Area Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 35 Regenerative Medicine in Pharma by Region- Market Overview ($Mn)
Figure 36 Regenerative Medicine in Pharma by Region Share - 2021 & 2027 (%)
Figure 37 North America Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 38 Europe Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 39 Asia-Pacific Market Revenue Opportunity Forecast, 2020-2027 ($Mn)
Figure 40 ROW Market Revenue Opportunity Forecast, 2020-2027 ($Mn)

Regenerative Medicine in Pharma Market Size, Share & Trends Analysis by Region, Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others), Route of Administration (Injectable, Oral, Topical), & Segment Forecast 2022-2028

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Tables

List of Tables

List of Figures

List of Figures